J&J Psoriasis Drug Might Pose Risk: FDA Staff
Medical review staff at the U.S. Food and Drug Administration have raised the possibility that long-term use of ustekinumab, an experimental treatment for psoriasis from Johnson & Johnson, could increase the...To view the full article, register now.
Already a subscriber? Click here to view full article